WVE · Wave Life Sciences Ltd.

$5.41 +0.21 (+4.04%) At close · Aug 14

Market Cap

$1.07B

197.05M

Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.

Fiscal 2024

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Paul Bolno	M.D., MBA President and Chief Executive Officer	$655,500	—	—	$3,064,934	$532,600	$19,266	$4,272,299
Kyle Moran	Chief Financial Officer	$497,200	—	—	$1,128,914	$279,675	$11,592	$1,917,381
Chandra Vargeese	Chief Technology Officer, Head of Platform Discovery Sciences	$487,540	—	—	$1,099,134	$287,975	$13,914	$1,888,563
Christopher Francis	Senior Vice President, Corporate Development and Head of Emerging Areas	$438,300	—	—	$870,312	$246,550	$11,260	$1,566,422

Fiscal 2023

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Paul Bolno	M.D., MBA President and Chief Executive Officer	$636,400	—	—	$2,744,529	$475,700	$17,671	$3,874,300
Chandra Vargeese	Chief Technology Officer, Head of Platform Discovery Sciences	$473,340	—	—	$1,051,535	$245,000	$13,464	$1,783,339
Kyle Moran	Chief Financial Officer	$471,300	—	—	$970,730	$243,900	$11,142	$1,697,072
Christopher Francis	Senior Vice President, Corporate Development and Head of Emerging Areas	$425,500	—	—	$871,059	$220,200	$10,710	$1,527,469

Fiscal 2022

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Paul Bolno	M.D., MBA President and Chief Executive Officer	$617,900	—	—	$1,565,220	$461,900	$22,977	$2,667,997
Chandra Vargeese	Chief Technology Officer, Head of Platform Discovery Sciences	$459,540	—	—	$521,740	$237,800	$12,714	$1,231,794
Kyle Moran	Chief Financial Officer	$439,875	—	—	$470,923	$227,600	$10,392	$1,148,790
Christopher Francis	Senior Vice President, Corporate Development and Head of Emerging Areas	$407,800	—	—	$391,305	$211,000	$540	$1,010,645

Executive changes

Person	Role	Change	Effective	Filed
Anne-Marie Li-Kwai-Cheung	Chief Development Officer	Appointed	2022-10-14	2022-09-26
Michael Panzara, M.D., MPH	Chief Medical Officer, Head of Therapeutics Discovery and Development	Resigned	2022-10-14	2022-09-26

Key facts CIK 1631574 CUSIP Y95308105 13F (30d) 234 filings 230 filers Visit website Investor relations